
Solaray Launches UNLIMIT Line Anchored by Creatine, NMN, and Liposomal NAD+
Key Takeaways
- Solaray’s strategy reframes longevity supplementation as a coordinated system, potentially improving consumer adherence and enabling multi-mechanism claims compared with single-ingredient, standalone positioning.
- Creatine + MBP combines well-characterized creatine monohydrate with milk basic protein and L-leucine, aligning muscle-performance and bone-density narratives with uneven but emerging human trial support for MBP.
The new longevity-focused system reflects a broader industry trend toward multi-product platforms targeting muscle, bone, and cellular health.
Solaray has introduced UNLIMIT, an 8-formula supplement system built around 3 areas the company frames as central to healthy aging: cellular energy, muscle health, and bone density.1
The launch reflects a broader pattern in the healthy-aging category, where suppliers are increasingly bundling multiple single-ingredient formulas into a coordinated system rather than positioning 1 product as a standalone solution.
"UNLIMIT was designed to simplify a complex category," noted Rachel Kilroy, Solaray’s senior director of product innovation. As the science around longevity has evolved, research has continued to point to the importance of supporting muscle, bone, and cellular health. We created UNLIMIT as a collection of targeted supplements rooted in these key areas, giving consumers a practical way to take a more focused approach to healthy aging."
What Ingredients Anchor the UNLIMIT Line, and What Does the Evidence Show?
The line's 3 hero formulas target distinct physiological systems. Creatine + MBP pairs creatine monohydrate, one of the most extensively studied ingredients in sports nutrition, with milk basic protein, a bovine milk-derived ingredient studied for its association with bone mineral density in some human trials, alongside the amino acid L-leucine.
The NMN formula is dosed to raise nicotinamide adenine dinucleotide, or NAD+, levels, a coenzyme that supports energy metabolism and is understood to decline with age. A systematic review of 10 randomized controlled trials involving 437 participants found that NMN supplementation, at doses ranging from 150 to 1,200 mg daily, was generally associated with improved physical performance measures, though the review's authors noted that evidence remains limited in scope and duration, with most trials lasting under 12 weeks.2
The line's Liposomal NAD+ formula uses liposomal delivery technology intended to improve absorption of the coenzyme directly, an approach distinct from NMN's precursor-based mechanism.
Why Are Genetics and Lifestyle Factors Central to How Solaray Frames This Product Line?
Genetics account for roughly 25% of variation in how people age, with lifestyle and environmental factors accounting for the remaining 75%.3 That framing is used to position UNLIMIT as addressing the modifiable portion of aging rather than claiming to alter genetic predisposition, a distinction relevant to how manufacturers might evaluate similar longevity-positioned product lines: the claim rests on a genetics research estimate rather than a demonstrated effect of any specific formula on aging outcomes.
What Should Manufacturers Note About the Line's Five Additional Formulas?
Beyond the 3 hero products, UNLIMIT includes liposomal glutathione, PEAK ATP, spermidine, fisetin, and NADH, each targeting a different mechanism, from antioxidant support to naturally occurring polyamine maintenance.
Notably, the level of independent human clinical evidence varies considerably across these 5 ingredients, with some, like PEAK ATP, supported by company-referenced clinical studies on physical performance, and others, like fisetin, drawing more heavily on preclinical research relative to confirmed human outcomes.
References
1. Solaray. Solaray launches UNLIMIT, a full product line built for longevity. PR Newswire. July 20, 2026. Accessed July 30, 2026.
2. Wen J, Syed B, Kim S, et al. Improved physical performance parameters in patients taking nicotinamide mononucleotide (NMN): a systematic review of randomized control trials. Cureus. 2024;16(8):e280185. doi:10.7759/cureus.280185
3. Caruso C, Ligotti ME, Accardi G, et al. How important are genes to achieve longevity? Int J Mol Sci. 2022;23(10):5635. doi:10.3390/ijms23105635





